<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02680158</url>
  </required_header>
  <id_info>
    <org_study_id>OCUN-009</org_study_id>
    <nct_id>NCT02680158</nct_id>
  </id_info>
  <brief_title>1-Day Study to Evaluate the Safety and Effectiveness of the Intranasal Lacrimal Neurostimulator</brief_title>
  <official_title>A Randomized, Controlled, Double-Masked, Multicenter Trial Designed to Evaluate Acute Tear Production With the Oculeve Intranasal Lacrimal Stimulator Compared to Two Control Applications in Patients With Aqueous Deficient Dry Eye</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oculeve, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oculeve, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare acute tear production produced by the Oculeve
      Intranasal Lacrimal Neurostimulator with two control devices in participants with aqueous
      tear deficiency.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, randomized, controlled, double-masked, multicenter clinical trial in
      which subjects with aqueous tear deficiency will receive three different device applications
      in a randomized sequence.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Three way cross-over study with 6 sequences.</intervention_model_description>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison between the active and control applications in acute tear production</measure>
    <time_frame>1-Day</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Device-related adverse events</measure>
    <time_frame>1-Day</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Corrected Distance Visual Acuity</measure>
    <time_frame>1-Day</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Slit Lamp Biomicroscopy</measure>
    <time_frame>1-Day</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Pulse Rate</measure>
    <time_frame>1-Day</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Oxygen Saturation</measure>
    <time_frame>1-Day</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Blood Pressure</measure>
    <time_frame>1-Day</time_frame>
  </other_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Dry Eye Syndrome</condition>
  <condition>Keratoconjunctivitis Sicca</condition>
  <arm_group>
    <arm_group_label>Intranasal : Extranasal : Sham</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Randomized sequence number 1: Oculeve Intranasal Lacrimal Neurostimulator applied intranasally, extranasally and intranasally with the Oculeve Sham device.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intranasal : Sham : Extranasal</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Randomized sequence number 2: Oculeve Intranasal Lacrimal Neurostimulator applied intranasally, Oculeve Sham device applied intranasally, and extranasally with the Oculeve Intranasal Lacrimal Neurostimulator.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Extranasal : Intranasal : Sham</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Randomized sequence number 3: Oculeve Intranasal Lacrimal Neurostimulator applied extranasally, intranasally, and applied intranasally with the Oculeve Sham device.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Extranasal : Sham : Intranasal</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Randomized sequence number 4: Oculeve Intranasal Lacrimal Neurostimulator applied extranasally, intranasally with the Oculeve Sham device, and intranasally with the Oculeve Intranasal Lacrimal Neurostimulator.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham : Intranasal : Extranasal</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Randomized sequence number 5: Oculeve Sham device, Oculeve Intranasal Lacrimal Neurostimulator applied intranasally and extranasally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham : Extranasal : Intranasal</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Randomized sequence number 6: Oculeve Sham device, Oculeve Intranasal Lacrimal Neurostimulator applied extranasally and intranasally.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Oculeve Intranasal Lacrimal Neurostimulator</intervention_name>
    <description>Active Neurostimulation device</description>
    <arm_group_label>Intranasal : Extranasal : Sham</arm_group_label>
    <arm_group_label>Intranasal : Sham : Extranasal</arm_group_label>
    <arm_group_label>Extranasal : Intranasal : Sham</arm_group_label>
    <arm_group_label>Extranasal : Sham : Intranasal</arm_group_label>
    <arm_group_label>Sham : Intranasal : Extranasal</arm_group_label>
    <arm_group_label>Sham : Extranasal : Intranasal</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Extranasal</intervention_name>
    <description>The active device applied extranasally</description>
    <arm_group_label>Intranasal : Extranasal : Sham</arm_group_label>
    <arm_group_label>Intranasal : Sham : Extranasal</arm_group_label>
    <arm_group_label>Extranasal : Intranasal : Sham</arm_group_label>
    <arm_group_label>Extranasal : Sham : Intranasal</arm_group_label>
    <arm_group_label>Sham : Intranasal : Extranasal</arm_group_label>
    <arm_group_label>Sham : Extranasal : Intranasal</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sham</intervention_name>
    <description>Sham device applied intranasally</description>
    <arm_group_label>Intranasal : Extranasal : Sham</arm_group_label>
    <arm_group_label>Intranasal : Sham : Extranasal</arm_group_label>
    <arm_group_label>Extranasal : Intranasal : Sham</arm_group_label>
    <arm_group_label>Extranasal : Sham : Intranasal</arm_group_label>
    <arm_group_label>Sham : Intranasal : Extranasal</arm_group_label>
    <arm_group_label>Sham : Extranasal : Intranasal</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects with aqueous tear deficiency

          -  Literate, able to speak English or Spanish, and able to complete questionnaires
             independently

          -  Willing to sign the informed consent and deemed capable of complying with the
             requirements of the study protocol

        Exclusion Criteria:

          -  Chronic or recurrent epistaxis, coagulation disorders or other conditions that, in the
             opinion of the investigator, may lead to clinically significant increased bleeding

          -  Nasal or sinus surgery including nasal cautery or significant trauma

          -  Cardiac demand pacemaker, implanted defibrillator or other implanted electronic device

          -  Diagnosis of epilepsy

          -  Corneal transplant in either or both eyes

          -  Participation in any clinical trial with a new active substance or a new device within
             30 days of the Screening Visit

          -  A woman who is pregnant, planning a pregnancy, or nursing at the Screening Visit
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edward Holland, MD</last_name>
    <role>Study Director</role>
    <affiliation>Cincinnati Eye Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Eye Care Group</name>
      <address>
        <city>Waterbury</city>
        <state>Connecticut</state>
        <zip>06708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Eye Consultants</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 21, 2016</study_first_submitted>
  <study_first_submitted_qc>February 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 11, 2016</study_first_posted>
  <disposition_first_submitted>April 7, 2017</disposition_first_submitted>
  <disposition_first_submitted_qc>April 7, 2017</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">April 10, 2017</disposition_first_posted>
  <last_update_submitted>April 7, 2017</last_update_submitted>
  <last_update_submitted_qc>April 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
    <mesh_term>Dry Eye Syndromes</mesh_term>
    <mesh_term>Keratoconjunctivitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

